Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A frontline three-drug regimen shows strong results in EGFR+ lung cancer. The phase 2 AMIGO-1 trial found that amivantamab, lazertinib, and pemetrexed achieved an 18-month progression-free survival rate of 66.7% in patients with EGFR-mutant NSCLC — significantly beating the ~50% benchmark set by osimertinib monotherapy. The confirmed overall response rate was an impressive 85%.
A frontline triple-drug combo clears a key hurdle in EGFR+ lung cancer
The phase 2 AMIGO-1 trial has met its primary end point, showing that combining amivantamab, lazertinib, and pemetrexed as first-line therapy significantly outperforms the historical standard. Conducted across 13 Brazilian sites in 54 patients with recurrent or metastatic EGFR-mutant NSCLC, the trial reported an 18-month progression-free survival (PFS) rate of 66.7% — well above the ~50% benchmark established by osimertinib monotherapy in the FLAURA trial.
The confirmed overall response rate hit 85%, with a median duration of response that hasn't yet been reached. Notably, patients with poor prognostic features — like TP53 co-mutations — fared better than historical comparisons with the doublet amivantamab plus lazertinib alone. However, the regimen came with meaningful toxicity, including a 17% rate of grade 5 adverse events; a protocol amendment capping pemetrexed at 8 cycles eliminated further treatment-related deaths.
By the Numbers
Why it matters: This trial adds to growing evidence that chemotherapy-intensified EGFR-directed regimens can push outcomes beyond what targeted therapy alone achieves — especially for high-risk patients. The safety signal warrants careful monitoring, but the results support further investigation of this modified triplet approach.
